Drug · DIN 02391678
SUBLINOX
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 5, 2019; first marketed January 28, 2013.
- Drug Identification Number (DIN)
- 02391678
- Company (DIN owner)
- Bausch Health, Canada Inc.Laval, Quebec, Canada
- Schedule
- Targeted substances (cdsa iv)
- Dosage form
- Tablet (Orally-Disintegrating)
- Route
- Sublingual
- Therapeutic class (ATC)
- Zolpidem N05CF02
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ZOLPIDEM TARTRATE | 5 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 5, 2019: NOC 22369New Drug Submission (NDS) · Change in product ownership
- January 8, 2015: NOC 16505New Drug Submission (NDS) · Transfer of drug identification number
- August 27, 2012: NOC 13588Supplement to a New Drug Submission (SNDS) · New strength and patient population: 5 mg tablet )orally disinegrating) for use in the elderly and in patients with hepatic impairment.
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “sublinox”. A notice may cover another product or only some lots: read it to see what it covers.
- Sublinox (zolpidem tartrate) - New Dosage Recommendations to Minimize Risk of Next-Day Impairment in Both Women and Men - For Health ProfessionalsJanuary 3, 2014 · Drugs · Dosage
- Sublinox (zolpidem tartrate) - New Dosage Recommendations to Minimize Risk of Next-Day Impairment in Both Women and Men - For the PublicJanuary 3, 2014 · Drugs · Dosage
Other DINs named SUBLINOX
- DIN 02370433 · Marketed